2015). NGS is gradually making its way into clinical research for diagnostic testing of hereditary disorders (Domchek et al. 2013; Grant et al. 2014; LaDuca et al. 2014; Yorczyk et al. 2014). Previous reports demonstrating NGS analysis of hereditary cancer-related genes identified germline mutations in breast and ovarian cancer patients (Walsh et al. 2011; Couch et al. 2014a; Cybulski et al. 2014; Kurian et al. 2014). However, the extent to which hereditary cancer genes other than BRCA1/2 are responsible for breast and ovarian cancer remains to be fully elucidated. This evidence concerns the gene BRCA1 and hereditary cancer.